Core Insights - Novartis has launched its innovative drug, Noreda (Acrylamide Hydrochloride Tablets), on JD Health, marking it as the first approved non-immunological therapy for adult patients with primary IgA nephropathy in China [1][2] - The drug is a highly selective endothelin A (ETA) receptor antagonist, filling a significant gap in non-hormonal basic treatments for this condition [2] Group 1 - Noreda is designed to reduce the risk of rapid disease progression in IgA nephropathy patients, which is prevalent among young adults aged 20 to 30 in China [1] - Clinical studies indicate that approximately 50% of IgA nephropathy patients with persistent proteinuria may progress to renal failure within 10 to 20 years if not effectively managed [1] - The collaboration between JD Health and Novartis aims to enhance the accessibility and precision of innovative treatments for patients nationwide [1][2] Group 2 - JD Health plans to deepen its focus on chronic disease management, particularly in kidney diseases, by leveraging its robust healthcare service ecosystem [2] - The introduction of Noreda is expected to provide new options for long-term disease management alongside existing standard treatments [2] - JD Health aims to offer comprehensive digital health management solutions for patients, improving the quality of life for those with kidney diseases and other chronic conditions [2]

Core Viewpoint - Novartis has launched its innovative drug, Noreida® (Acrylamide Hydrochloride Tablets), on JD Health, marking a significant advancement in the treatment of IgA nephropathy in adult patients in China [1][2]. Group 1: Product Launch and Significance - Noreida® is the first approved non-immunotherapy for reducing the risk of rapid disease progression in adult patients with IgA nephropathy in China [1]. - It is currently the only high-selective endothelin A (ETA) receptor antagonist for this indication in the country [1]. - The drug fills a gap in non-hormonal foundational treatments for this condition, providing a new option for clinicians to manage the disease alongside existing standard treatments [2]. Group 2: Market and Patient Impact - IgA nephropathy is a common primary glomerular disease prevalent among young adults in China, particularly those aged 20 to 30 [1]. - If not effectively controlled, approximately 50% of patients with persistent proteinuria may progress to renal failure within 10 to 20 years post-diagnosis, necessitating lifelong dialysis or kidney transplantation [1]. - JD Health aims to leverage its supply chain capabilities and professional pharmacist services to ensure that innovative drugs like Noreida® reach patients more quickly and effectively across the country [1]. Group 3: Future Directions - JD Health plans to deepen its collaboration with leading global pharmaceutical companies like Novartis to introduce cutting-edge treatment options and focus on comprehensive digital health management solutions for chronic diseases, including kidney diseases [2]. - This strategy aims to enhance the quality of life for patients with kidney diseases and a broader population suffering from chronic conditions [2].